Grant✓ Small businesses may apply

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

National Institutes of Health

Opportunity #: RFA-TR-25-002
Agency: National Institutes of Health
ALN (CFDA): 93.350
Status: posted
Posted: Dec 6, 2024
Closes: Jul 2, 2027
Funding instrument: Grant
Category: Health
Cost sharing required: No

Who can apply

•State governments
•Native American tribal organizations (other than Federally recognized tribal governments)
•County governments
•For profit organizations other than small businesses
•Public housing authorities/Indian housing authorities
•Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
•Private institutions of higher education
•Independent school districts
•City or township governments
•Small businesses
•Special district governments
•Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
•Native American tribal governments (Federally recognized)
•Public and State controlled institutions of higher education
•Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Synopsis

This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

Contact

National Institutes of Health · grantsinfo@nih.gov

View full notice on Grants.gov ↗